Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Therapy

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial

Leukemia volume 19, pages 34–38 (2005)Cite this article

Abstract

The recombinant urate oxidase, rasburicase (Elitek™, Sanofi-Synthelabo, Inc.), has recently received regulatory approval for the prevention and treatment of hyperuricemia in children with leukemia, lymphoma, and solid tumors. Prior to approval, 682 children and 387 adults in the US and Canada received rasburicase on compassionate-use basis. Uric acid concentration declined rapidly in both adult and pediatric patients after rasburicase treatment. Similar responses were observed in patients treated with subsequent courses. Possible drug-related adverse events, including allergic reactions, were uncommon. These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Pui C-H . Introduction – optimal treatment of malignancies associated with hyperuricemia. Semin Hematol 2001; 38 (Suppl 10): 1–3.

    Article  Google Scholar 

  2. Jeha S . Tumor lysis syndrome. Semin Hematol 2001; 38 (Suppl 10): 4–8.

    Article  CAS  Google Scholar 

  3. Baecksgaard L, Sorensen JB . Acute tumor lysis syndrome in solid tumors – a case report and review of the literature. Cancer Chemother Pharmacol 2003; 51: 187–192.

    Google Scholar 

  4. Stapleton FB, Strother DR, Roy III S, Wyatt RJ, McKay CP, Murphy SB . Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 1988; 82: 863–869.

    CAS  PubMed  Google Scholar 

  5. Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small non-cleaved cell lymphoma: a Pediatric Oncology Group Study. J Clin Oncol 1996; 14: 1252–1261.

    Article  CAS  Google Scholar 

  6. Krakoff IH, Meyer RL . Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. JAMA 1965; 193: 89–94.

    Article  Google Scholar 

  7. DeConti RC, Calabresi P . Use of allopurinol for the prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966; 274: 481–486.

    Article  CAS  Google Scholar 

  8. Greene ML, Fujimoto WY, Seegmiller JE . Urinary xanthine stones – a rare complication of allopurinol therapy. New Engl J Med 1969; 280: 426–427.

    Article  CAS  Google Scholar 

  9. Band PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Banerjee TK et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970; 283: 354–357.

    Article  CAS  Google Scholar 

  10. Andreoli SP, Clark JH, McGuire WA, Bergstein JM . Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986; 109: 292–298.

    Article  CAS  Google Scholar 

  11. Pui C-H . Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 2002; 3: 433–452.

    Article  CAS  Google Scholar 

  12. Pui C-H, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997; 11: 1813–1816.

    Article  CAS  Google Scholar 

  13. Pui C-H, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19: 697–704.

    Article  CAS  Google Scholar 

  14. Goldman S, Holcenberg JS, Finklestein JZ, Hutchison R, Kreissman S, Johnson FL et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma and leukemia at high risk of tumor lysis. Blood 2001; 97: 2998–3003.

    Article  CAS  Google Scholar 

  15. Bosly A, Sonnet A, Pinkerton CR, McCowage G, Bron D, Sanz MA et al. Rasburicase (Recombinant Urate Oxidase) for the management of hyperuricemia in patients with cancer – report of an International Compassionate Use Study. Cancer 2003; 98: 1048–1054.

    Article  CAS  Google Scholar 

  16. Pui C-H, Jeha S, Irwin D, Camitta B . Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15: 1505–1509.

    Article  CAS  Google Scholar 

  17. Van den Berg H, Reintsema AM . Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol 2004; 15: 175–176.

    Article  CAS  Google Scholar 

  18. Choukair MK . Blood chemistries/body fluids. In: Siberry GK, Iannone R (eds). The Harriet Lane Handbook: A Manual for Pediatric House Officers, 15th edn. St Louis: Mosby-Year Book Inc, 1996, pp 119–130.

    Google Scholar 

  19. Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E, Pacquement H et al. Urate oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Ann Oncol 2002; 13: 789–795.

    Article  CAS  Google Scholar 

  20. Atra A, Gerard M, Hobson R, Imeson J, Ashley S, Pinkerton C . Improved cure rate in children with B-cell acute lymphoblastic leukemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL) – results of the UKCCSG 9003 protocol. Br J Cancer 1998; 77: 2281–2285.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grant CA-21765 from the National Cancer Institute, a grant from Sanofi-Synthelabo, Inc., a Center of Excellence grant from the State of Tennessee and American Lebanese Syrian Associated Charities (ALSAC). C-H Pui is the American Cancer Society FM Kirby Clinical Research Professor.

Author information

Authors and Affiliations

  1. St. Jude Children's Research Hospital, Memphis, TN, USA

    S Jeha & C-H Pui

  2. MD Anderson Cancer Center, Houston, TX, USA

    H Kantarjian

  3. Alta Bates Comprehensive Cancer Center, Berkeley, CA, USA

    D Irwin

  4. Children's Hospital of Orange County, Orange, CA, USA

    V Shen

  5. Washington University School of Medicine, St. Louis, MO, USA

    S Shenoy

  6. Texas Children's Cancer Center, Houston, TX, USA

    S Blaney

  7. Midwest Children's Cancer Center Medical College of Wisconsin, Milwaukee, WI, USA

    B Camitta

Authors
  1. S Jeha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Irwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Shenoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Blaney
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Camitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C-H Pui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Jeha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeha, S., Kantarjian, H., Irwin, D. et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 19, 34–38 (2005). https://doi.org/10.1038/sj.leu.2403566

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403566

Keywords

This article is cited by

Search

Advanced search

Quick links